Legal marijuana flat-Earthers, like U.S. Attorney General Jeff Sessions, have tried many methods to discredit breakthroughs in medical cannabis, which is now legal in 28 states.
This is of course all despite thousands of documented positive cases where marijuana helped sufferers cope with afflictions like cancer, multiple sclerosis, and epilepsy.
But, as you'll see, these efforts at discrediting cannabis stop at the U.S. border. Several other countries, especially the United Kingdom, have created a far more favorable climate for cannabis research and innovation.
Don't get me wrong – I'm extremely bullish on the future state of American public cannabis research and its potential to bring new products to a huge market, largely because the momentum for marijuana is all but totally unstoppable here. That's going to be huge for the already surging U.S. market.
But the stock I'm about to show you is set to soar (again) right now…
U.S. Public Marijuana Research Faces an Uphill Battle
Legal cannabis opponents sought for years to discredit studies from groups perceived, sometimes unfairly, as pro-marijuana advocates or supported by businesses with a stake in the industry.
More recently, anti-weed crusaders have been trying to downplay findings within academic research projects greenlighted by the federal government, calling them "unproven" or "inconsistent."
You see, many domestic researchers are working with a deck stacked against them.
Over the last week, media sources like The Washington Post and PBS extensively outlined complaints from researchers analyzing marijuana's potential medical effects.
For one, the government continues to list marijuana as a Schedule I drug, along with heroin and cocaine. That has stymied involvement from test subjects, many of whom remain fearful of prosecution.
The U.S. studies that are up and running, like completed ones of the past, often suffer from a quality problem – not of the researchers but of the product itself.
A Washington Post article now making the rounds shows the marijuana used in domestic research is almost always significantly poorer in quality than what is produced by the best legal growers in North America. Several of those growers are analyzed among the 30 stocks included in The Roadmap to Marijuana Millions, which I released last September. Many of those shares have already paid triple-digit gains.
But the federal government mandates researchers, like those working at the University of Mississippi, use government-grown weed. And of course, like many pursuits, cannabis growing is not the federal government's forte.
Flat out, it is inferior product to commercially grown marijuana in so many ways: The chemical potency is significantly less, the consistency is dryer, the smell is weaker, and the government doesn't even test for common contaminants like mold, yeast, or elevated pesticide levels.
It's like the old computer science adage: garbage in, garbage out. It's nearly impossible to get highly credible and consistent results with that kind of halfhearted government commitment to the research material.
As I said earlier, the situation in other countries, like the United Kingdom, is far, far better. And that's good news for the future of weed investing.
The British Are Coming… and They're Bringing Serious Money
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top technology financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
Michael is 100% independent and receives absolutely no compensation from companies he writes about. His ideas are completely his own.
So, it probably goes without saying that you won't ever be left in the dark about breaking innovations, ahead-of-their-time technologies, and breakout companies on the cusp of changing the world once you join this world.